Literature DB >> 11774170

High expression of CD34-positive sinusoidal endothelial cells is a risk factor for hepatocellular carcinoma in patients with HCV-associated chronic liver diseases.

S Ohmori1, K Shiraki, K Sugimoto, T Sakai, K Fujikawa, H Wagayama, K Takase, T Nakano.   

Abstract

CD34 has been widely used for the assessment of sinusoid-like neoangiogenesis in hepatocellular carcinoma (HCC). Recently, it was demonstrated that CD34-positive cells isolated from human peripheral blood differentiate into endothelial cells and contribute to neoangiogenesis in adults. We investigated the localization and the substantial role of CD34-positive endothelial cells in the liver with hepatitis C virus (HCV)--associated chronic liver diseases. Liver tissue sections obtained by biopsy from 56 patients with HCV-associated chronic liver diseases by were examined immunohistochemically using anti-CD34, anti-von Willebrand factor (vWF), and anti-vascular endothelial growth factor (VEGF) antibodies. CD34 was stained in the sinusoid, showing dotty, linear, semicircular, or circular patterns. However, sinusoidal expression of vWF was not substantially identified in the same specimens, indicating the existence of sinusoidal CD34-positive but vWF-negative endothelial cells. We classified these cells as CD34 LI and found that CD34 LI was correlated with the expression of VEGF. Among 34 patients with advanced-stage disease, the cumulative incidence of HCC was significantly higher in patients with CD34 LI >or= 12 (n = 16) than in those with CD34 LI < 12 (n = 18; P = .009). Moreover, among several clinicopathologic risk factors, CD34 LI could be recognized as an independently significant factor for development of HCC (relative risk, 7.36; P = .019). We conclude that CD34-positive endothelial cells are regulated by several factors, such as VEGF, and might play a substantial role in hepatocarcinogenesis. Furthermore, high expression of CD34-positive sinusoidal endothelial cells is a risk factor for HCC in patients with HCV-associated chronic liver diseases. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11774170     DOI: 10.1053/hupa.2001.29678

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  11 in total

1.  A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment.

Authors:  Galina A Gusarova; I-Ching Wang; Michael L Major; Vladimir V Kalinichenko; Timothy Ackerson; Vladimir Petrovic; Robert H Costa
Journal:  J Clin Invest       Date:  2006-12-14       Impact factor: 14.808

2.  Angiogenesis: a phenomenon which aggravates chronic liver disease progression.

Authors:  Michał Kukla
Journal:  Hepatol Int       Date:  2012-07-26       Impact factor: 6.047

3.  In hepatic venous outflow obstruction, alcoholic liver disease, and nonalcoholic fatty liver disease, centrilobular scars, CD34+ vessels, and keratin 7+ hepatocytes are in close proximity.

Authors:  Susumu Matsukuma; Hiroaki Takeo; Yoshitaka Utsumi; Kimiya Sato
Journal:  Virchows Arch       Date:  2017-01-23       Impact factor: 4.064

Review 4.  Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Martine Soell; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mosaad Megahed
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 5.  Role of liver sinusoidal endothelial cells in liver diseases.

Authors:  Jordi Gracia-Sancho; Esther Caparrós; Anabel Fernández-Iglesias; Rubén Francés
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-15       Impact factor: 46.802

6.  Microvessel density and clinicopathologic characteristics in hepatocellular carcinoma with and without cirrhosis.

Authors:  Ivan Chebib; Meer Taher Shabani-Rad; Michelle S Chow; James Zhang; Zu-Hua Gao
Journal:  Biomark Insights       Date:  2007-02-14

7.  Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.

Authors:  H Yoshiji; S Kuriyama; J Yoshii; Y Ikenaka; R Noguchi; D J Hicklin; Y Wu; K Yanase; T Namisaki; M Yamazaki; H Tsujinoue; H Imazu; T Masaki; H Fukui
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

8.  Microvessel density of malignant and benign hepatic lesions and MRI evaluation.

Authors:  Jian-Ping Lu; Jian Wang; Tao Wang; Yi Wang; Wei-Qing Wu; Li Gao
Journal:  World J Gastroenterol       Date:  2004-06-15       Impact factor: 5.742

9.  Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD.

Authors:  Marcos Pasarín; Vincenzo La Mura; Jorge Gracia-Sancho; Héctor García-Calderó; Aina Rodríguez-Vilarrupla; Juan Carlos García-Pagán; Jaime Bosch; Juan G Abraldes
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

10.  Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC.

Authors:  Saieh Hajighasemlou; Mohsen Nikbakht; Saeedreza Pakzad; Samad Muhammadnejad; Safoora Gharibzadeh; Milad Mirmoghtadaei; Fariba Zafari; Iman Seyhoun; Jafar Ai; Javad Verdi
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.